

February 10, 2022  
Symbio Pharmaceuticals Limited  
(Securities Code: 4582)  
Fuminori Yoshida  
Representative Director  
President and Chief Executive Officer

## Notice concerning non-operating expenses

Symbio Pharmaceuticals Limited (the “Company”) today announced its non-operating expenses for the fourth quarter of the fiscal year ending December 31, 2021 (from October 1, 2021 to December 31, 2021).

### 1. Details of Non-Operating Expenses

The Company recorded a foreign exchange loss of 1,308 thousand yen under non-operating expenses for the fourth quarter of the fiscal year ending December 31, 2021 (from October 1, 2021 to December 31, 2021) due to recent fluctuations in foreign exchange rates. Together with a foreign exchange loss of 18,878 thousand yen for the third quarter ended September 30, 2021, the Company recorded a total foreign exchange loss of 20,186 thousand yen for the fiscal year ending December 31, 2021.

### 2. Future Outlook

Regarding the impact of the above non-operating expense on the results of Company operations, please refer to the “Summary of Financial Statements for the Fiscal Year Ended December 31, 2021 [Japanese GAAP] (Non-consolidated)” announced today.

### [Contact]

Investor Relations  
Tel: +81(0)3 5472 1125